ClinicalTrials.Veeva

Menu

Evaluation of Adult Onset Still Disease Classification Criteria and Differential Diagnosis at Eighteen Months of Follow-up (AOSD-DIF)

C

Central Hospital, Nancy, France

Status

Completed

Conditions

Adult Onset Still Disease

Treatments

Other: diagnosis criteria performance

Study type

Observational

Funder types

Other

Identifiers

NCT04750863
2021PI001

Details and patient eligibility

About

Adult Onset Still Disease (AOSD) is an acquired inflammatory disease of unknown etiology, presenting with non specific symptoms. Its diagnosis rely on sets of criteria, i.e. Fautrel Criteria and Yamaguchi Criteria. However, differential diagnosis might appear during follow-up of patients. The aim of this study is to assess diagnostic performance of Fautral and Yamaguchi Criteria after 18 months of follow-up, and to describe differential diagnosis appearing during follow-up.

Full description

Adult Onset Still Disease (AOSD) is an acquired inflammatory disease of unknown etiology, presenting with non specific symptoms. Other conditions such as cancer, infection or other inflammatory disease might mimick its symptoms. Its diagnosis rely on sets of criteria, i.e. Fautrel Criteria and Yamaguchi Criteria. However, differential diagnosis might appear during follow-up after an initial diagnosis of AOSD. The aim of this study is to assess diagnostic performance of Fautral and Yamaguchi Criteria after 18 months of follow-up, and to describe differential diagnosis appearing during follow-up.

Enrollment

312 patients

Sex

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adults
  • with glycosylated ferritin dosage for suspected adult onset still disease
  • with at least 18 month of follow-up

Exclusion criteria

  • known infectious disease
  • known cancer
  • known active connective tissue disease or vasculitis

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems